新型冠状病毒肺炎治疗期间的药物性肝损伤
Drug-Induced Liver Disturbance During the Treatment of COVID-19.
作者信息
Zhai Guanghua, Li Meifen, Wang Ying, Wu Jian
机构信息
Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Department of Infection Management, Suzhou Hosptial Affiliated to Nanjing Medical University, Suzhou, China.
出版信息
Front Pharmacol. 2021 Aug 18;12:719308. doi: 10.3389/fphar.2021.719308. eCollection 2021.
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, at the end of 2019. The World Health Organization named the resulting infectious disease as coronavirus disease-2019 (COVID-19). Many studies concluded that patients infected with SARS-CoV-2 have different degrees of liver disturbance. However, the relationship between the drugs used for COVID-19 treatment and liver disturbance remains controversial. It is essential to evaluate the potential liver damage caused by various drugs in order to help guide clinical practice. This review analyzed the effect of drugs on hepatic function during the treatment of COVID-19.
2019年底，中国武汉爆发了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫情。世界卫生组织将由此引发的传染病命名为冠状病毒病-2019（COVID-19）。许多研究得出结论，感染SARS-CoV-2的患者存在不同程度的肝脏功能紊乱。然而，用于COVID-19治疗的药物与肝脏功能紊乱之间的关系仍存在争议。评估各种药物可能引起的肝损伤对于指导临床实践至关重要。本综述分析了COVID-19治疗期间药物对肝功能的影响。
Zotero 插件